Benzinga
Benzinga
Actualités France
Bourse
Economie
Général
Actualités Américaines
Bourse
Bénéfices
Economie
Marchés prédictifs
Marchés privés
Autres marchés
Recommandations des analystes
Trading
Communiqués de presse
Mondial
Asie
Crypto-monnaies
Actualités cryptos
Altcoins
Bitcoin
Dogecoin
Ethereum
Shiba Inu
NFT
Éducation
Investir en crypto
Investir en bourse
Forex
Benzinga
samedi, novembre 21
Actualités France
Bourse
Economie
Général
Actualités Américaines
Bourse
Bénéfices
Economie
Marchés prédictifs
Marchés privés
Autres marchés
Recommandations des analystes
Trading
Communiqués de presse
Mondial
Asie
Crypto-monnaies
Actualités cryptos
Altcoins
Bitcoin
Dogecoin
Ethereum
Shiba Inu
NFT
Éducation
Investir en crypto
Investir en bourse
Forex
Cameco Corp
CCJ
NYSE
Liste de surveillance
Get Report
Trade with Public
Get Report
Trade with Public
$58.00
-3.42
-5.57%
À la clôture: Nov 20, 4:00 PM EST
$59.60
1.60
2.77%
Après les heures: 7:58 PM EST
Get Report
Aperçu
Actualités
Graphiques
Prévisions de résultats
Objectifs de cours
Données financières
Sentiment
Actionnariat
Dividendes
Comparer
Options
Rapport sur les stocks
PRO
Pourquoi cela bouge-t-il ?:
Shares of uranium and nuclear-related companies are trading lower as invest...
Dividende:
La date ex-dividende est le dans 9 jours
Cameco Financials
Cameco (CCJ) financial statements — income, revenue, gross margin and key metrics.
Earnings & Guidance News
PRO
Cameco Affirms FY2026 Sales Guidance of $2.398B-$2.580B vs $2.440B Est
Cameco (NYSE:CCJ) affirms FY2026 sales outlook from $2.398 billion-$2.580 billion to $2.398 billion-$2.580 billion vs $2.440 billion estimate.
Benzinga Newsdesk
PRO
Cameco Q3 Adj EPS $0.00 and Sales $619.000M Miss $767.666M Estimate
Cameco (TSX:CCO) reported quarterly sales of $619.000 million which missed the analyst consensus estimate of $767.666 million by 19.37 percent. This is a 0.65 percent increase over sales of $615.000 million the same
Benzinga Newsdesk
ExxonMobil, AbbVie On Deck Friday As Energy, Drug Growth Face Test
ExxonMobil headlines Friday’s reports, with investors watching whether strong energy production can sustain a sharp earnings recovery. AbbVie, Chevron, AstraZeneca, BP, Sanofi, General Dynamics, Regeneron
Benzinga Insights
PRO
Cameco Raises FY2026 Sales Guidance from $2.245B-$2.417B to $2.398B-$2.580B vs $2.390B Est
Cameco (NYSE:CCJ) raises FY2026 sales outlook from $2.245 billion-$2.417 billion to $2.398 billion-$2.580 billion vs $2.390 billion estimate.
Benzinga Newsdesk
PRO
Cameco Lowers FY2026 Sales Guidance from $3.130B-$3.370B to $2.398B-$2.580B vs $3.440B Est
Cameco (TSX:CCO) lowers FY2026 sales outlook from $3.130 billion-$3.370 billion to $2.398 billion-$2.580 billion vs $3.440 billion estimate.
Benzinga Newsdesk
PRO
Cameco Q2 Adj. EPS $0.13 Misses $0.36 Estimate, Sales $588.000M Beat $534.360M Estimate
Cameco (NYSE:CCJ) reported quarterly earnings of $0.13 per share which missed the analyst consensus estimate of $0.36 by 63.89 percent. This is a 74.51 percent decrease over earnings of $0.51 per share from the same
Benzinga Newsdesk